<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CARBAMAZEPINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CARBAMAZEPINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#professionSpecificInformation" data-toggle="tab">Profession specific information</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Focal and secondary generalised tonic-clonic seizures</span>,
                <span class="indication">Primary generalised tonic-clonic seizures</span>,
            </h4>
            <p class="specificity"><span class="route">By rectum</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100&#8211;200 mg 1&#8211;2 times a day, increased in steps of 100&#8211;200 mg every 2 weeks; usual dose 0.8&#8211;1.2 g daily in divided doses; increased if necessary up to 1.6&#8211;2 g daily in divided doses.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Reduce initial dose.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Up to 1 g daily in 4 divided doses for up to 7 days, for short-term use when oral therapy temporarily not possible.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Trigeminal neuralgia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100 mg 1&#8211;2 times a day, some patients may require higher initial dose, increased in steps of 100&#8211;200 mg every 2 weeks, adjusted according to response, usual dose 200 mg 3&#8211;4 times a day; increased if necessary up to 1.6 g daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of bipolar disorder unresponsive to lithium</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 400 mg daily in divided doses, increased in steps of 100&#8211;200 mg every 2 weeks until symptoms controlled; usual dose 400&#8211;600 mg daily; maximum 1.6 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of alcohol withdrawal</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 800 mg daily in divided doses, then reduced to 200 mg daily usual treatment duration 7&#8211;10 days, dose to be reduced gradually over 5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diabetic neuropathy</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100 mg 1&#8211;2 times a day, increased in steps of 100&#8211;200 mg every 2 weeks, adjusted according to response, usual dose 200 mg 3&#8211;4 times a day; increased if necessary up to 1.6 g daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Focal and generalised tonic-clonic seizures</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Initially 5 mg/kg once daily, dose to be taken at night, alternatively initially 2.5 mg/kg twice daily, then increased in steps of 2.5&#8211;5 mg/kg every 3&#8211;7 days as required; maintenance 5 mg/kg 2&#8211;3 times a day, increased if necessary up to 20 mg/kg daily.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 100&#8211;200 mg 1&#8211;2 times a day, then increased to 200&#8211;400 mg 2&#8211;3 times a day, increased if necessary up to 1.8 g daily, dose should be increased slowly.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Suppositories of 125&#8239;mg may be considered to be approximately equivalent in therapeutic effect to tablets of 100&#8239;mg but final adjustment should always depend on clinical response (plasma concentration monitoring recommended).</p>
            </section>
        
        
        
      </section>




      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Metabolism impaired in advanced liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>AV conduction abnormalities (unless paced)</li>
            <li>history of bone-marrow depression</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Allergic skin reactions, aplastic anaemia, ataxia, blood disorders, blurring of vision, dermatitis, dizziness, drowsiness, dry mouth, eosinophilia, fatigue, haemolytic anaemia, headache, hyponatraemia (leading in rare cases to water intoxication), leucopenia, nausea, oedema, thrombocytopenia, unsteadiness, urticaria, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Constipation, diarrhoea, involuntary movements (including nystagmus), visual disturbances,
              </p>
              <p>
                <strong>rare:</strong> Abdominal pain, aggression, agitation, anorexia, cardiac conduction disorders, confusion, delayed multi-organ hypersensitivity disorder, depression, dysarthria, hallucinations, hepatitis, hypertension, hypotension, jaundice, lymph node enlargement, muscle weakness, paraesthesia, peripheral neuropathy, restlessness, systemic lupus erythematosus, vanishing bile duct syndrome,
              </p>
              <p>
                <strong>veryRare:</strong> Arthralgia, muscle spasm, acne, alopecia, alterations in skin pigmentation, angle-closure glaucoma, aseptic meningitis, AV block with syncope, circulatory collapse, conjunctivitis, dyspnoea, exacerbation of coronary artery disease, galactorrhoea, gynaecomastia, hearing disorders, hepatic failure, hirsutism, hypercholesterolaemia, impaired male fertility, interstitial nephritis, muscle pain, neuroleptic malignant syndrome, osteomalacia, osteoporosis, pancreatitis, photosensitivity, pneumonia, pneumonitis, psychosis, pulmonary hypersensitivity, purpura, renal failure, sexual dysfunction, Stevens-Johnson syndrome, stomatitis, sweating, taste disturbance, thromboembolism, thrombophlebitis, toxic epidermal necrolysis, urinary frequency, urinary retention,
              </p>
              <p>
                <strong>notKnown:</strong> Suicidal ideation,
              </p>
        
        
            <section class="advice">
              <h3 class="specificity">In adults</h3>
              <p>Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment and in the elderly. Patients should be offered a modified-release preparation to reduce the risk of side-effects; altering the timing of medication may also be beneficial.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">In children</h3>
              <p>Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment. Children should be offered a modified-release preparation to reduce the risk of side-effects; altering the timing of medication may also be beneficial.</p>
            </section>
        
            <section class="overdosageInformation">
                <h3>Emergency treatment of poisoning; active elimination techniques</h3>
              <p>Repeated doses of activated charcoal by mouth enhance the elimination of some drugs after they have been absorbed; repeated doses are given after overdosage with carbamazepine.</p><p>The usual dose of activated charcoal in adults and children over 12 years of age is 50&#8239;g initially then 50&#8239;g every 4 hours. Vomiting should be treated (e.g. with an antiemetic drug) since it may reduce the efficacy of charcoal treatment. In cases of intolerance, the dose may be reduced and the frequency increased (e.g. 25&#8239;g every 2 hours or 12.5&#8239;g every hour) but this may compromise efficacy.</p><p>In children under 12 years of age, activated charcoal is given in a dose of 1&#8239;g/kg (max. 50&#8239;g) every 4 hours; the dose may be reduced and the frequency increased if not tolerated.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">In children</h3>
              <p>Oral liquid has been used rectally&#8212;should be retained for at least 2 hours (but may have laxative effect).</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Blood, hepatic, or skin disorders</h3>
              <p>Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Carbamazepine (oral) for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/carbamazepine-oral-preventing-seizures-0">www.medicinesforchildren.org.uk/carbamazepine-oral-preventing-seizures-0</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac disease
          </li>
          <li>
            history of haematological reactions to other drugs
          </li>
          <li>
            may exacerbate absence and myoclonic seizures
          </li>
          <li>
            skin reactions
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
        <ul>
          <li>
            <p>Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.</p>
          </li>
          <li>
            <p>Carbamazepine should be withdrawn immediately in cases of aggravated liver dysfunction or acute liver disease. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <p>Plasma concentration for optimum response 4&#8211;12 mg/litre (20&#8211;50 micromol/litre) measured after 1&#8211;2 weeks.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Manufacturer recommends blood counts and hepatic and renal function tests (but evidence of practical value uncertain).</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>
            <i>Suppositories</i> not licensed for use in trigeminal neuralgia or prophylaxis of bipolar disorder.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Use in the treatment of alcohol withdrawal is an unlicensed indication.</p><p>Use in diabetic neuropathy is an unlicensed indication.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Switching between formulations</h3>
              <p>Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer's product.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>When stopping treatment with carbamazepine for bipolar disorder, reduce the dose gradually over a period of at least 4 weeks.</p>
            </section>
      </section>



      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <p>Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative&#8212;risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).</p>
            </section>
      </section>


      <section class="tab-pane" id="professionSpecificInformation">
        <h2>Profession specific information</h2>

          <h3>Dental practitioners</h3>
        
            <section class="dentalPractitionersFormulary">
              <p>Carbamazepine Tablets may be prescribed.</p>
            </section>
      </section>


      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Antiepileptic hypersensitivity syndrome associated with carbamazepine. See under <xref format="dita" href="#PHP78230" type="bookmark" namespace="/treatment-summaries/epilepsy">Epilepsy</xref> for more information.</p><p>Caution&#8212;cross-sensitivity reported with oxcarbazepine and with phenytoin.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CARBAMAZEPINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP76521"><a href="../medicinalForm/PHP76521.html" data-target="#PHP76521" data-action="load">Tablet</a></div>
            <div id="PHP76527"><a href="../medicinalForm/PHP76527.html" data-target="#PHP76527" data-action="load">Modified-release tablet</a></div>
            <div id="PHP76555"><a href="../medicinalForm/PHP76555.html" data-target="#PHP76555" data-action="load">Oral suspension</a></div>
            <div id="PHP76542"><a href="../medicinalForm/PHP76542.html" data-target="#PHP76542" data-action="load">Suppository</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
